ABS-201

ABS-201
Clinical data
Other namesABS201
Routes of
administration		Subcutaneous injection[1]
Drug classProlactin receptor monoclonal antibody
ATC code
  • None

ABS-201 is an AI-designed monoclonal antibody against the prolactin receptor (PRLR) currently in Phase 1/2a clinical trial[2][3][4] for the treatment of androgenic alopecia (pattern hair loss) and endometriosis.[1][5][6][7] It is taken by subcutaneous injection.[1][6] ABS-201 is a possible first-in-class drug with a novel mechanism of action in the potential treatment of hair loss.[8] ABS-201 is under development by Absci.[9][10]

It is believed that ABS-201 works by activating dormant hair follicles and causing them to move from the telogen phase to the anagen phase.[6][7] In human ex vivo scalp model studies, ABS-201 stimulated hair regrowth, prolonged anagen phase, blocked catagen phase, inhibited telogen effluvium, and blocked hair from losing color.[11][12] ABS-201 has been found to produce robust hair regrowth as compared with minoxidil in mice and balding macaques.[6][7]

The clinical trial for ABS-201 is being overseen by prominent hair loss researcher Rodney Sinclair,[6] one of the principal investigators in minoxidil clinical trials.[13][14] The chemical structure of the drug does not yet appear to have been disclosed.[1]

See also

References

  1. ^ a b c d "ABS 201". AdisInsight. 7 October 2025. Retrieved 14 November 2025.
  2. ^ Absci Pty Ltd. (2025-12-30). A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Healthy Adult Participants With and Without Androgenetic Alopecia (Report). clinicaltrials.gov.
  3. ^ "ABS 201 - Absci - AdisInsight". adisinsight.springer.com. Retrieved 2026-02-05.
  4. ^ "Absci Initiates First-in-Human Trial of AI-Designed Antibody ABS-201 for Hair Loss Treatment". MedPath. 2025-12-04. Retrieved 2026-02-05.
  5. ^ "Delving into the Latest Updates on ABS-201(Absci Corp) with Synapse". Synapse. 25 October 2025. Retrieved 14 November 2025.
  6. ^ a b c d e Frederickson E (20 October 2025). "A New Hair Loss Drug Could Cure Balding and Reverse Graying". Popular Mechanics. Retrieved 14 November 2025.
  7. ^ a b c Kahn A (2024). "Absci 2024 R&D Day Presentation". Absci Corporation.
  8. ^ "Absci Initiates First-in-Human Trial of AI-Designed Antibody ABS-201 for Hair Loss Treatment". MedPath. 2025-12-04. Retrieved 2026-02-05.
  9. ^ "ABS 201 - Absci - AdisInsight". adisinsight.springer.com. Retrieved 2026-02-05.
  10. ^ "Delving into the Latest Updates on ABS-201(Absci Corp) with Synapse". synapse.patsnap.com. Retrieved 2026-02-05.
  11. ^ "ABS-201 KOL SEMINAR". Absci. December 12, 2025.
  12. ^ "ABS 201 - Absci - AdisInsight". adisinsight.springer.com. Retrieved 2026-02-05.
  13. ^ Applied Biology, Inc. (2018-10-04). Minoxidil Response Testing in Females With Female Pattern Hair Loss (Report). clinicaltrials.gov.
  14. ^ "A 32-week randomized, placebo-controlled, double-blinded pilot study to compare the efficacy and safety of low-dose oral minoxidil in male and female patients with patterned hair loss (androgenetic alopecia) followed by a 24-week open label extension period". MedPath. 2021-11-15. Retrieved 2026-02-05.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.